

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross® has confirmed that the shortages for Jamp-Candesartan 32 mg Tablet (DIN 02386534), Candesartan 32 mg Tablet (DIN 02435845) and Candesartan 32 mg Tablet (DIN 02528266) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **September 25, 2023**. The following grouping was removed from the Critical Supply Product List **August 24, 2023**.

CANDESARTAN CILEXETIL

32 MG TABLET

00002399105	APO-CANDESARTAN	APX	\$ 0.2281
00002445816	AURO-CANDESARTAN	AUR	\$ 0.2281
00002435845	CANDESARTAN	SNS	\$ 0.2281
00002528266	CANDESARTAN	SIV	\$ 0.2281
00002379295	CANDESARTAN	AHI	\$ 0.2281
00002386534	JAMP CANDESARTAN	JPC	\$ 0.2281
00002527030	NRA-CANDESARTAN	NRA	\$ 0.2281
00002391228	PMS-CANDESARTAN	PMS	\$ 0.2281
00002380714	RAN-CANDESARTAN	RAN	\$ 0.2281
00002417340	SANDOZ CANDESARTAN	SDZ	\$ 0.2281
00002366339	TEVA-CANDESARTAN	TEV	\$ 0.2281
00002311658	ATACAND	AZC	\$ 1.3488

Alberta Blue Cross has confirmed that the shortage for Sandoz Sitagliptin-Metformin 50 mg/1000 mg Tablet (DIN 02503972) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **October 10, 2023**. The following grouping was removed from the Critical Supply Product List **September 8, 2023**.

PHOSPHATE MONOHYDRATE

50 MG / 1000 MG ORAL TABLET

00002503972	SANDOZ SITAGLIPTIN-METFORMIN	SDZ	\$ 0.8893
00002333872	JANUMET	MFC	\$ 1.7465

continued next page

PHARMACY BENEFACT

continued from previous page

Temporary benefits added to the ADBL

Due to the unavailability of Janumet XR 50 mg/1000 mg Extended-Release Tablet (DIN 02416794) manufactured by Merck Canada Inc., **Sandoz Sitagliptin-Metformin XR 50/1000 mg ER Tablet (DIN 02529114)** manufactured by Sandoz Canada Inc. will be considered a temporary benefit for the *Alberta Drug Benefit List (ADBL)*. This grouping was added to the Critical Supply Product List **August 27, 2023**.

As of **August 27, 2023**, all claims for Sandoz Sitagliptin-Metformin XR 50/1000 mg ER Tablet (DIN 02529114) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/providers/pharmacy-home.php.

Removal of temporary benefits from the ADBL

Due to the shortage of Teva-Cephalexin 125 25 mg/mL Oral Suspension (DIN 00342106) and Teva-Cephalexin 250 50 mg/mL Oral Suspension (DIN 00342092), the following products were added as temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

DIN	Temporary Benefit
02497743	Auro-Cephalexin 25 mg/mL Oral Suspension
02497751	Auro-Cephalexin 50 mg/mL Oral Suspension
02528444	Jamp-Cephalexin 50 mg/mL Oral Suspension
02469170	Lupin-Cephalexin 25 mg/mL Oral Suspension
02469189	Lupin-Cephalexin 50 mg/mL Oral Suspension

Alberta Blue Cross has confirmed Teva-Cephalexin 125 25 mg/mL Oral Suspension (DIN 00342106) and Teva-Cephalexin 250 50 mg/mL Oral Suspension (DIN 00342092) are now available.

As a result, the above products will no longer be considered a temporary benefit for *ADBL* **after October 9, 2023**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

